When recalls or warnings are issued for medical devices, drugs, or other health care products by the FDA or manufacturers, medical providers are advised to take a thorough and documented approach in response. Such measures help reduce potential liability and ensure ongoing patient care.
Providers may need to consult legal counsel to clarify their responsibilities in these situations. The guidance emphasizes starting with the most up-to-date information from agencies or manufacturers. Notices usually describe risks, benefits, and recommended actions related to the affected product.
Common recommendations include treatment steps to minimize risk, device correction or removal, monitoring patients, and considering available alternatives. Providers are urged to follow manufacturer instructions exactly and document each step taken. If recommended actions cannot be followed, the reasons should be recorded. For each patient encounter involving a recall or warning, details should be added to their medical record. If a patient refuses advice related to a recall or warning, this informed refusal should also be documented.
Manufacturers often assign responsibility for notifying patients about recalls or warnings directly to licensed health care providers. According to typical language in such notices: “[Manufacturer’s name] will not communicate with patients directly about this issue. If patients have been impacted as part of this issue, health care providers have the responsibility to inform patients and/or update a patient’s care pathway.”
Health care professionals are encouraged to use resources like electronic health records (EHR) and patient lists to identify those affected—especially if they prescribed the product or used it in treatment. In cases involving over-the-counter medications that were not prescribed by the provider, obligations may be less extensive.
Efforts should be made to contact all affected patients using multiple communication methods such as phone calls and emails; at least two attempts are recommended. For serious recalls, sending letters with return receipt requested is advised.
High volumes of patient inquiries can result from recalls and warnings; therefore, offices should designate an informed staff member who can address questions and know when provider appointments are needed. This respondent might use prepared scripts for consistency in communication. Some providers opt to share verbatim manufacturer communications with patients but must document every call made.
Financial responsibility for follow-up visits and procedures varies depending on the situation; sometimes insurers or manufacturers will assist with costs while at other times claims must be filed by patients themselves.
If legal action occurs against a manufacturer due to harm caused by recalled products, thorough documentation of all steps taken can help protect facilities and individual providers from being named in lawsuits.
To receive updates on FDA safety alerts regarding drugs and devices, interested parties can subscribe via www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/subscribe-medwatch-safety-alerts.
